Issued on behalf of Aleen Inc.
VANCOUVER – Baystreet.ca News Commentary – So far, the latest Q3 funding surge[1] has shown digital wellness building speed again as investors are backing AI that cuts costs and fixes workflow pain. At the same time, the FDA’s new feedback push on real-world performance signals a clearer path for responsible rollouts and coverage[2]. With both money and rules aligning, leaders building practical, reimbursable AI look set to benefit, including Aleen Inc. (CSE: ALEN-U), CareCloud, Inc. (NASDAQ: CCLD), Waystar Holding Corp. (NASDAQ: WAY), Tempus AI, Inc. (NASDAQ: TEM), and Whitehawk Therapeutics, Inc. (NASDAQ: WHWK).
Analysts see the U.S. AI wellness market compounding fast, with a 2025-2033 CAGR of 36.76% and multi-billion-dollar headroom in play, according to a recent market outlook[3]. Adoption drivers are strengthening too, as platforms and organizations steer AI toward operational efficiency, user engagement, and improved wellness support[4].
Aleen Inc. (CSE: ALEN-U) is making waves in the digital wellness sector with its artificial intelligence platform designed to help people gain personalized insights based on wellness indicators and user inputs. The Canadian technology company, which went public on the Canadian Securities Exchange in June 2025, has developed a system that allows users to input wellness indicators and receive personalized wellness insights—without providing medical advice or replacing healthcare professionals.
Based in Ontario, Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their wellness, the company has positioned itself to capture a portion of this growing demand.
The company's main product, the Aleen AI system, can be accessed two ways. First, users can visit the Aleen website to gain personalized wellness insights based on the information they provide. This free service helps raise awareness about the company's capabilities while encouraging users to take a more active role in understanding their well-being. Second, businesses can integrate Aleen Inc.'s technology through its API (Application Programming Interface), which allows telemedicine platforms and wellness apps to embed the company's AI-powered assessments into their own services.
The company generates revenue through its API offerings, which are available through two pricing models: a per-call option where businesses pay only for the number of requests they use, and a monthly subscription model for companies that need consistent access to the health assessment technology. This flexible approach allows Aleen Inc. to serve both smaller operations and larger enterprise clients.
Looking ahead to 2026, Aleen Inc. has announced ambitious expansion plans. The company is preparing to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place. Additionally, the company will offer smart analytics features designed to help users track trends in their wellness indicators and support informed lifestyle choices.
To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, including enhancements to its AI algorithms and expansion of the wellness indicator database. Another 30% would go toward sales and marketing efforts, including global outreach to potential business partners. Product expansion would receive 20% of the funding for developing mobile apps and specialized modules for corporate wellness programs.
The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities. Instead, the platform serves as a first step in helping people understand their wellness indicators and make informed lifestyle choices.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman.
CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CareCloud, Inc. (NASDAQ: CCLD) has announced a definitive agreement to acquire MAP App, the industry-leading hospital benchmarking tool created by the Healthcare Financial Management Association (HFMA), with the transaction scheduled to close on October 1, 2025. The acquisition expands CareCloud's SaaS-based ecosystem with a proven revenue cycle management performance measurement tool used by top hospitals and healthcare organizations nationwide, supported by a long-term joint marketing agreement with HFMA.
"Aligned with HFMA's mission, MAP App provides hospitals with the revenue cycle insights needed to improve transparency, efficiency, and financial results. Together, we look forward to advancing this tool to the next level of innovation and impact," said Stephen Snyder, Co-Chief Executive Officer of CareCloud. "This acquisition enables CareCloud to deliver actionable insights and uncover opportunities for measurable improvement, strengthened by the capabilities of our AI Center of Excellence and the synergies created through our recent acquisition of Medsphere's hospital IT business."
CareCloud serves more than 40,000 providers with AI and technology-enabled solutions that help clients increase financial and operational performance while streamlining clinical workflows. The acquisition will enable expansion of MAP App's capabilities, including AI-driven insights, while accelerating growth throughout the hospital market without having a material financial impact on the company in 2025.
Waystar Holding Corp. (NASDAQ: WAY) recently completed its acquisition of Iodine Software, uniting one of the industry's largest financial datasets with one of the largest clinical datasets to strengthen its AI platform and deliver transformational outcomes for healthcare providers. Iodine's client base of more than 1,000 hospitals and health systems expands Waystar's total addressable market by over 15%, with the acquisition expected to be immediately accretive to gross margin and adjusted EBITDA margin, and accretive to revenue growth and non-GAAP net income per diluted share in 2027.
"Iodine joining Waystar brings together comprehensive clinical and financial intelligence on a single AI-powered platform — a unique differentiator in the market," said Matt Hawkins, Chief Executive Officer of Waystar. "This further powers automation in the revenue cycle, strengthens financial performance, and leverages combined data assets to drive a continuously learning AI platform that maximizes client outcomes."
Uniting Iodine's expertise in the critical stage between care delivery and claim submission provides Waystar expansive visibility across the healthcare payment ecosystem, fueling next-generation AI capabilities that prevent revenue leakage and ensure providers are paid fully and accurately. Waystar serves approximately 30,000 clients representing over 1 million distinct providers, with its enterprise-grade platform annually processing over 6 billion healthcare payment transactions totaling over $1.8 trillion in annual gross claims.
Tempus AI, Inc. (NASDAQ: TEM) recently announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support clinical trial designs by focusing on patient populations with the highest level of demonstrated real-world unmet need, centering on research spanning Whitehawk Therapeutics' antibody drug conjugate portfolio targeting clinically validated proteins broadly expressed in high-potential cancer indications such as lung and gynecological cancers.
"Tempus' comprehensive, multimodal data, paired with Whitehawk's ADC drug development expertise, create a powerful foundation to validate the potential of their portfolio in a promising class of targeted cancer therapeutics," said Ryan Fukushima, Chief Operating Officer at Tempus. "We're committed to working in tandem with our biotech collaborators to uncover actionable insights from our AI platform so they can make smarter, faster decisions throughout the drug development process."
Tempus operates one of the world's largest libraries of multimodal data with an AI-enabled operating system designed to make that data accessible and useful, providing precision medicine solutions to physicians for personalized patient care while facilitating discovery, development and delivery of optimal therapeutics. The collaboration aims to establish concordance between RNA and IHC expression of Whitehawk Therapeutics' ADC targets, with RNA testing offering objective, reproducible and scalable advantages that could enhance identification of appropriate patients for ADC therapies.
"A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline. An important aspect of this partnership will be continuing to establish the concordance between RNA and IHC expression of our targets. Because RNA testing is objective, reproducible and scalable, establishing it as a reliable alternative to the more subjective IHC methods could enhance our ability to readily identify appropriate patients for our ADC therapies."
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition.
--
SOURCES CITED:
1. https://rockhealth.com/insights/q3-2025-market-overview-signals-out-of-sync/
2. https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device
3. https://www.globenewswire.com/news-release/2025/09/17/3151864/28124/en/United-States-AI-in-Healthcare-Market-Trends-and-Competition-Report-2025-2033.html
4. https://www.healthcaredive.com/news/healthcare-ai-investment-focused-profit-margins-roi-bain-company-klas-research/802531/
Related Stories
